 |
|
Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply
Hyeyeon Hong, Jonggi Choi
Clin Mol Hepatol. 2024;30(2):272-273. Published online 2024 Feb 21 DOI: https://doi.org/10.3350/cmh.2024.0123
|
|
Citations to this article as recorded by
 Reply to correspondence on “Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide”
Pin-Nan Cheng, Ming-Lung Yu
Clinical and Molecular Hepatology.2024; 30(4): 1031. CrossRef
|